About: http://data.cimple.eu/news-article/7b1af4cf558a232c6cf240f65bef843a783375a9af8603cc05a42b64     Goto   Sponge   Distinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • US pharmaceutical firm Eli Lilly on Tuesday paused a late-stage trial of its experimental lab-produced antibody treatment against Covid-19 over an unspecified safety concern, the company said. "Lilly is supportive of the decision by the independent DSMB (data safety monitoring board) to cautiously ensure the safety of the patients participating in this study," a spokesperson told AFP in a statement. The Phase 3 randomized control trial is a study of hospitalized Covid-19 patients that began in August across more than 50 sites in the United States, Denmark and Singapore with the aim of recruiting 10,000 people. It is sponsored by the US National Institutes of Health. Monoclonal antibody treatments have been making headlines recently after US President Donald Trump credited one therapy, developed by biotech firm Regeneron, with curing him of Covid-19. Both Lilly and Regeneron last week applied to the US Food and Drug Administration for emergency use authorizations for their treatments. It was not immediately clear whether the pause would affect other clinical trials that Lilly is running for Covid-19, for example among patients with mild to moderate forms of the disease or as a potential prophylaxis. Monoclonal antibodies are a relatively new class of drugs that are best known for treating certain types of cancer and autoimmune disease. Our own immune systems produce antibodies, which are infection-fighting molecules, and vaccines teach our bodies to be prepared to make the right ones for particular pathogens. Another potential strategy is to give a patient fighting a disease the antibodies of someone who has already recovered. This is known as convalescent plasma, but it's hard to procure plasma on a big enough scale to use it very widely. The Covid-19 treatment which was being studied in the paused trial was based on an effective antibody Lilly found in a recovered patient that was then mass produced in a lab. It is administered intravenously by drip. Lilly didn't disclose any detail about the safety concern or how many people are affected. But generally speaking, mild side effects of IV administered therapies can include fevers, chills, and fatigue, while moderate to severe infusions can cause chest pain and shortness of breath. ia/dw
schema:headline
  • Lilly pauses Covid-19 antibody treatment trial over safety concern
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software